What is Ascribe Bioscience?
Founded in 2017 and headquartered in Ithaca, New York, Ascribe Bioscience is dedicated to the development of environmentally-friendly biopesticides. The company's focus on sustainable agricultural solutions positions it within a growing market segment driven by increasing demand for eco-conscious farming practices. The recent major enterprise-level funding suggests a transition towards scaling operations and expanding market reach.
How much funding has Ascribe Bioscience raised?
Ascribe Bioscience has raised a total of $15M across 1 funding round:
Private Equity
$15M
Private Equity (2025): $15M, investors not publicly disclosed
What's next for Ascribe Bioscience?
The substantial capital infusion, particularly the recent major strategic investment, indicates a pivotal growth phase for Ascribe Bioscience. This financing is expected to accelerate product development, enhance manufacturing capabilities, and broaden distribution channels for its biopesticide offerings. The company is likely to focus on solidifying its market position and potentially exploring new product lines or geographical expansions, leveraging this strategic backing to drive innovation and operational efficiency in the competitive agricultural technology landscape.
See full Ascribe Bioscience company page
